Table 5 Tumour response rate (eligible population)

From: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

 

No. of patients (%)

 

ASA404-CP ( n =34)

CP ( n =36)

Investigator assessment

 Number of patients available for assessment

32 (100.0)

31 (100.0)

 Partial response (confirmed)

11 (34.4)

9 (29.0)

 Partial response (unconfirmed)

2 (6.3)

3 (9.7)

 Stable disease

14 (43.8)

10 (32.3)

 Progressive disease

5 (15.6)

9 (29.0)

Independent assessment

 Number of patients available for assessmenta

32 (100.0)

27 (100.0)

 Partial response

10 (31.3)

6 (22.2)

 Stable disease

21 (65.6)

19 (70.4)

 Progressive disease

1 (3.1)

2 (7.4)

  1. ASA404-CP=ASA404 combined with carboplatin and paclitaxel; CP=carboplatin and paclitaxel.
  2. aTumour response could not be evaluated in 11 eligible patients by independent assessment due to: patient death before second tumour assessment (n=3); patient withdrawal before second tumour assessment (n=3); disease progression after cycle 1 and no subsequent scans available (n=2); no target lesion present (n=2); or no baseline scan available (n=1).
Back to article page